Hike Capital appeared to be the VC, which was created in 2015. The leading representative office of defined VC is situated in the Beijing. The fund was located in Asia if to be more exact in China.
The current fund was established by Anna Xu, Mark Yang. Besides them, we counted 3 critical employees of this fund in our database.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. The fund has specific favorite in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Automotive, Food and Beverage. Among the various public portfolio startups of the fund, we may underline Huohua Siwei, Hetao101, Ruff Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
The fund is generally included in 2-6 deals every year. Deals in the range of more than 100 millions dollars are the general things for fund. The real fund results show that this VC is 15 percentage points more often commits exit comparing to other companies. When the investment is from Hike Capital the average startup value is more than 1 billion dollars. The top activity for fund was in 2018.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Hike Capital, startups are often financed by Matrix Partners China, Lightspeed China Partners, IDG Capital. The meaningful sponsors for the fund in investment in the same round are Sequoia Capital China, IDG Capital, Lightspeed China Partners. In the next rounds fund is usually obtained by IDG Capital, Sequoia Capital China, XVC.
Related Funds
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Orienspace | $92M | 24 Jan 2024 | Beijing, Beijing, China | ||
Hopewell Therapeutics | $25M | 02 Jun 2023 | Boston, Massachusetts, United States | ||
Orienspace | $59M | 20 May 2022 | Beijing, Beijing, China | ||
Artivila Therapeutics | $15M | 31 Mar 2022 | Shenzhen, Guangdong, China | ||
Xbiome | $100M | 22 Dec 2021 | Futian District, Guangdong Province, China | ||
Doublefs | $100M | 17 Jun 2021 | - | ||
Megatronix | $15M | 17 May 2021 | Dongcheng District, Beijing, China | ||
Yuanbao Insurance Research Institute | $154M | 10 May 2021 | China, Beijing, China | ||
Quansu Zaixian | $30M | 30 Jul 2020 | Qingyang District, Sichuan, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Orienspace | $92M | 24 Jan 2024 | Beijing, Beijing, China | ||
Hopewell Therapeutics | $25M | 02 Jun 2023 | Boston, Massachusetts, United States | ||
Orienspace | $59M | 20 May 2022 | Beijing, Beijing, China | ||
Artivila Therapeutics | $15M | 31 Mar 2022 | Shenzhen, Guangdong, China | ||
Xbiome | $100M | 22 Dec 2021 | Futian District, Guangdong Province, China | ||
Doublefs | $100M | 17 Jun 2021 | - | ||
Megatronix | $15M | 17 May 2021 | Dongcheng District, Beijing, China | ||
Yuanbao Insurance Research Institute | $154M | 10 May 2021 | China, Beijing, China | ||
Quansu Zaixian | $30M | 30 Jul 2020 | Qingyang District, Sichuan, China |